Relay Therapeutics, Inc. (RLAY) Stock

Relay Therapeutics, Inc. (RLAY) is a Healthcare stock trading at $15.89 (as of 2026-06-18), with a market capitalization of $2.69B and a trailing P/E of -9.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

I can’t create a compliant description because the SEC 10-K “Business” (Item 1) text for Relay Therapeutics, Inc. wasn’t provided. Please paste the Item 1 business section (or the relevant excerpts), and I’ll rewrite a 1–2 sentence (~45 words) neutral JSON description based only on that text.

Valuation — source: SEC EDGAR (first-party)
Price	$15.89
Market Cap	$2.69B
P/E Ratio	-9.0
EV / EBITDA	-8.5
Price / Book	4.19
Price / Sales	252.13
DCF Value (model)	$-21.99
DCF Upside vs Price	-238.3%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$15.36M
Net Margin	-1800.6%
Return on Equity	-42.5%
Current Ratio	22.13
Revenue Growth (YoY)	53.4%
EPS Growth (YoY)	-31.8%
FCF Growth (YoY)	-6.1%

Financial Health — source: SEC EDGAR
Altman Z-Score	26.35 (safe)

Valuation vs Sector & Industry
Stock P/E	-9.0
Sector P/E (Healthcare)	21.0
Industry P/E (Pharmaceutical Products)	17.3
vs Sector	-143.0%
vs Industry	-152.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	SB INVESTMENT ADVISERS (UK) LTD ($277.65M)
Institutional Holders Tracked	10
Congressional Trades (recent)	1

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Sanjiv K. Patel
Employees	259
Country	US
IPO Date	2020-07-16

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.